Abstract: A wound dressing which comprises alginate characterized in that the alginate has a mannuronate content of 50% to 80% has a molecular weight of 7,000 to 40,000 and has a monovalent:polyvalent of from 10 to 30:70 to 90.

Abstract: Highly absorbent alginate fibers are described which have use in the manufacture of dressings. The fibers and dressings described are highly swellable while also being soluble, rather than just being soluble. This is a considerable advantage for use in environments where high absorption coupled with biodegradability is desired, for example, in wound dressings such as dressings for ulcers or burns.

Abstract: A process for preparing an alginate rope, which process comprises the steps of: (a) extruding an aqueous solution of a water soluble alginate into a coagulation bath; (b) contacting the extruded water soluble alginate with a source of a cation capable of forming a water insoluble alginate salt so as to produce a tow of water insoluble alginate fibers; (c) twisting the water insoluble alginate fibers of the tow; and (d) stretching the fibers up to 250% of their original length. The alginate rope prepared according to the process of the invention may be used as a surgical pack material or in the treatment of cavity wounds.

Abstract: A wound dressing having a lower skin-contacting layer, an upper occlusive layer and an absorbent layer therebetween, at least one seal is provided which defines an absorbent region for preventing the migration of body fluids from the absorbent region and to provide a moist wound environment including the optional inclusion of a wound healing substance.

Abstract: Compounds of the formula ##STR1## inhibit endothelin, wherein: R is phenyl, naphthyl or biphenyl, each of which may be substituted.

Abstract: This invention is directed to solid compositions, for example, lyophilized forms, of fibrin monomer. These compositions are useful wherever fibrin monomer could be employed, e.g., as a surgical sealant to provide hemostasis.

Abstract: The subject invention relates to fibrin sealants. More specifically, the subject invention relates to the use of a fibrin sealant wherein a composition comprising fibrin monomer or a composition comprising noncrosslinked fibrin is utilized as a component of the fibrin sealant.

Abstract: A device for separating components, such as fibrin I from blood, by way of centrifugation about a central axis of rotation comprises a first annular chamber defined by an outer cylindrical wall and an inner cylindrical wall, both walls being concentrically accommodated about the axis of rotation, and by a top wall and a bottom wall, where the top wall or the bottom wall is formed by a piston body displaceable within the first chamber. The device comprises furthermore a second chamber communicating with said first chamber through a first conduit and being defined by an outer cylindrical wall concentrically accommodated about the axis of rotation, said bottom wall of the first chamber, and another bottom wall. The second chamber is adapted to be placed below the first chamber during the centrifugation.

Abstract: An apparatus for separating a blood component, e.g., fibrin monomer, from blood or plasma ?comprises! includes a container ?(110)! with a reaction chamber for receiving the plasma, where ?said! the reaction chamber is defined by an outer wall and ?comprises! includes means for supplying ?said! the reaction chamber with an agent for converting the fibrinogen content of the plasma into a non-cross-linked fibrin polymer. The apparatus ?comprises furthermore! also includes a device for centrifuging the reaction chamber with the plasma and ?said! the agent to a degree sufficient for separating the non-cross-linked fibrin polymer from the plasma, for depositing ?said! the polymer on the outer wall of the reaction chamber, and for expelling the remaining plasma from the reaction chamber. The container ?(110) comprises! includes means for supplying the reaction chamber with a solvent for dissolving ?said! the non-cross-linked fibrin polymer.

Abstract: Method for forming a polyurethane based adhesive composition in which a reaction mixture of at least one NCO-terminated prepolymer and a polyhydroxy compound is heated at a temperature and for a length of time sufficient to provide a gel content of from about 30 to 42% by weight and a molecular weight of extractables of at least about 45,000. Polyurethane based adhesives prepared by the method and medical devices employing the same are also disclosed.

Abstract: The present invention relates to a multi-layered wound dressing particularly for use as a dressing on highly exudating wounds.

Abstract: Compositions and methods for avidin immobilized on an inert support material, e.g., agarose, are disclosed. The compositions have high activity levels of avidin and may further include a bulking agent, e.g., maltose, and a protectant to maintain the stability and integrity of the avidin agarose during lyophilization and terminal sterilization processes. A dry composition, and wet compositions such as a gel, slurry or suspension having avidin immobilized on an inert support material are disclosed. The dry composition has at least 1000 biotin binding units of activity, and the wet compositions have at least 50 units of binding activity. These compositions have applicability in any instance where avidin agarose and/or the avidin/biotin technology are useful. In particular, the present compositions are useful in an enzyme capture system to prepare fibrin monomer useful for fibrin sealants.

Abstract: A device for separating components, such as fibrin I from blood, by way of centrifugation about a central axis of rotation comprises a first annular chamber defined by an outer cylindrical wall and an inner cylindrical wall, both walls being concentrically accommodated about the axis of rotation, and by a top wall and a bottom wall, where the top wall or the bottom wall is formed by a piston body displaceable within the first chamber. The device comprises furthermore a second chamber communicating with said first chamber through a first conduit and being defined by an outer cylindrical wall concentrically accommodated about the axis of rotation, said bottom wall of the first chamber, and another bottom wall. The second chamber is adapted to be placed below the first chamber during the centrifugation.

Abstract: Alginate fabrics have, in conjuction with charcoal cloth, been used in wound dressings for malodorous wounds and there are commercial examples of such wound dressings. A problem associated with known alginate wound dressings which employ charcoal cloth is that the dressing is a relatively rigid structure. Furthermore, the known dressings have been constrained to the use of charcoal cloth which limits the absorptive properties thereof for wound odorants due to the fixed surface area of the cloth. We have now developed an alginate fabric which alleviates the above problems, and there is provided by the present invention an alginate fabric having particulate charcoal dispersed therein.

Abstract: A permanent, biocompatible material for soft tissue augmentation. The biocompatible material comprises a matrix of smooth, round, finely divided, substantially spherical particles of a biocompatible ceramic material, close to or in contact with each other, which provide a scaffold or lattice for autogenous, three dimensional, randomly oriented, non-scar soft tissue growth at the augmentation site. The augmentation material can be homogeneously suspended in a biocompatible, resorbable lubricious gel carrier comprising a polysaccharide. This serves to improve the delivery of the augmentation material by injection to the tissue site where augmentation is desired. The augmentation material is especially suitable for urethral sphincter augmentation, for treatment of incontinence, for filling soft tissue voids, for creating soft tissue blebs, for the treatment of unilateral vocal cord paralysis, and for mammary implants. It can be injected intradermally, subcutaneously or can be implanted.

Abstract: Alginate fibres comprising at least one medicament incorporated into the structure thereof, the medicament being present at a level of at least 10% by weight, based on the weight of the alginate fibre with no incorporated medicament.

Abstract: Methods and devices for preventing and/or treating an adverse reaction of the skin to the presence of a skin-sensitizing and/or skin-irritating agent by administering an effective amount of a loop diuretic alone or in combination with at least one mast cell degranulator or at least one glucocorticosteroid.

Abstract: Methods for producing poly?urethane-(meth)acrylate!-based adhesives in which an isocyanate-terminated prepolymer is reacted to convert the isocyanate terminal groups into groups capable of cross-linking with each other, excess isocyanate groups are quenched with an isocyanate group quenching compound and the resulting prepolymer is then irradiated or heated to form the polyurethane-based adhesives, and adhesives produced thereby. Alternatively, a hydroxyl-terminated prepolymer is reacted with a reagent having isocyanate and methacrylate groups to form a prepolymer which is then irradiated or heated.

Abstract: This invention relates to the use of an adhesive composition for the preparation of a wound dressing, or part of a wound dressing, for treating wounds by reducing the volume of exudate produced by the wound.

Abstract: An improved wound dressing is provided which comprises a backing layer bearing a reference marking, a hydrocolloid layer and a release layer. The hydrocolloid swells in use. This swelling can be seen or felt through the backing layer. When the swelling extends to or beyond the reference marking, the dressing should be changed to prevent leaking. Thus, the dressing can be left in place for as long as possible, but not so long as to damage the underlying skin.